[go: up one dir, main page]

MX2019007738A - Anticuerpos contra el vih ampliamente neutralizantes y métodos de uso de ellos. - Google Patents

Anticuerpos contra el vih ampliamente neutralizantes y métodos de uso de ellos.

Info

Publication number
MX2019007738A
MX2019007738A MX2019007738A MX2019007738A MX2019007738A MX 2019007738 A MX2019007738 A MX 2019007738A MX 2019007738 A MX2019007738 A MX 2019007738A MX 2019007738 A MX2019007738 A MX 2019007738A MX 2019007738 A MX2019007738 A MX 2019007738A
Authority
MX
Mexico
Prior art keywords
methods
hiv antibodies
neutralizing hiv
widely neutralizing
widely
Prior art date
Application number
MX2019007738A
Other languages
English (en)
Inventor
Nussenzweig Michel
J Bjorkman Pamela
Scharf Louise
T Freund Natalia
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of MX2019007738A publication Critical patent/MX2019007738A/es

Links

Classifications

    • C07K16/114—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C07K16/1145—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con anticuerpos contra el VIH-1 ampliamente neutralizantes y potentes, con estuches con métodos de uso de ellos.
MX2019007738A 2016-12-27 2017-12-22 Anticuerpos contra el vih ampliamente neutralizantes y métodos de uso de ellos. MX2019007738A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662439339P 2016-12-27 2016-12-27
US201762444946P 2017-01-11 2017-01-11
PCT/US2017/068235 WO2018125813A1 (en) 2016-12-27 2017-12-22 Broadly neutralizing anti-hiv-1 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2019007738A true MX2019007738A (es) 2019-09-05

Family

ID=62710381

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007738A MX2019007738A (es) 2016-12-27 2017-12-22 Anticuerpos contra el vih ampliamente neutralizantes y métodos de uso de ellos.
MX2024010027A MX2024010027A (es) 2016-12-27 2019-06-26 Anticuerpos contra el vih ampliamente neutralizantes y metodos de uso de ellos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024010027A MX2024010027A (es) 2016-12-27 2019-06-26 Anticuerpos contra el vih ampliamente neutralizantes y metodos de uso de ellos.

Country Status (10)

Country Link
US (3) US11325966B2 (es)
EP (1) EP3562505A4 (es)
JP (3) JP7041898B2 (es)
CN (2) CN110621338B (es)
AU (2) AU2017387041B2 (es)
BR (1) BR112019013468A8 (es)
CA (1) CA3048837A1 (es)
IL (1) IL267673B2 (es)
MX (2) MX2019007738A (es)
WO (1) WO2018125813A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11325966B2 (en) * 2016-12-27 2022-05-10 The Rockefeller University Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof
CA3102859A1 (en) 2018-07-03 2020-01-09 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
US20210292396A1 (en) * 2018-07-27 2021-09-23 International Aids Vaccine Initiative Enginerred antibodies to hiv env
EP3849612A4 (en) * 2018-09-14 2022-07-06 The Rockefeller University ANTI-HIV ANTIBODIES 10-1074 VARIANTS
TWI762925B (zh) 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
CN120775062A (zh) 2019-07-16 2025-10-14 吉利德科学公司 Hiv疫苗及其制备和使用方法
CN116157416A (zh) 2020-08-25 2023-05-23 吉利德科学公司 靶向hiv的多特异性抗原结合分子及其使用方法
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20230107288A (ko) 2020-11-11 2023-07-14 길리애드 사이언시즈, 인코포레이티드 gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법
CN119677546A (zh) 2022-07-12 2025-03-21 吉利德科学公司 Hiv免疫原性多肽和疫苗及其用途
EP4577242A1 (en) 2022-08-26 2025-07-02 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
EP1381685B1 (en) 2001-04-26 2005-09-14 Ecopia Biosciences Inc. Genes and proteins for the biosynthesis of polyketides
US20070060743A1 (en) 2001-05-16 2007-03-15 Tang Y Tom Novel nucleic acids and polypeptides
AU2002337885B1 (en) 2001-10-16 2003-04-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human ummunodeficiency virus selected by Env-CD4-co-receptor complexes
US20070292390A1 (en) 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
JP2009542611A (ja) 2006-07-03 2009-12-03 ザパロイド・リミテッド アルファ−シヌクレイン凝集の阻害
JP2013505236A (ja) 2009-09-16 2013-02-14 デューク ユニバーシティー Ｈｉｖ−１抗体
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
DK2710033T3 (da) * 2011-05-17 2021-03-08 Univ Rockefeller Human immundefektvirus-neutraliserende antistoffer og fremgangsmåder til anvendelse deraf
WO2013036130A1 (en) 2011-09-09 2013-03-14 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
WO2014040025A2 (en) * 2012-09-10 2014-03-13 International Aids Vaccine Initiative Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
IL285049B (en) * 2012-10-18 2022-07-01 California Inst Of Techn Broad-spectrum neutralizing antibodies against the AIDS virus
EP2914629A1 (en) * 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
AU2014224049B2 (en) * 2013-02-28 2018-11-29 Therabiol, Inc. HIV antigens and antibodies
WO2015048610A1 (en) 2013-09-27 2015-04-02 Duke University Hiv-1 immunogens and broadly neutralizing hiv-1 antibodies
CN106102837B (zh) 2013-12-02 2020-10-13 艾伦戴蒙德艾滋病研究中心 双特异性hiv-1-中和抗体
US10421803B2 (en) 2014-01-31 2019-09-24 The Rockefeller University Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
EP3110844B1 (en) 2014-02-28 2020-02-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
US20160033532A1 (en) 2014-08-01 2016-02-04 International Aids Vaccine Initiative Mammalian protein co-recognition by broadly neutralizing antibodies as modified immunogens for re-elicitation
WO2016127179A2 (en) * 2015-02-06 2016-08-11 Kadmon Corporation, Llc Immunomodulatory agents
US11149082B2 (en) 2016-10-17 2021-10-19 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
US11325966B2 (en) * 2016-12-27 2022-05-10 The Rockefeller University Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof

Also Published As

Publication number Publication date
CA3048837A1 (en) 2018-07-05
JP2022095613A (ja) 2022-06-28
US11897940B2 (en) 2024-02-13
EP3562505A4 (en) 2020-11-11
JP7460091B2 (ja) 2024-04-02
US20220348642A1 (en) 2022-11-03
AU2017387041B2 (en) 2024-12-12
MX2024010027A (es) 2024-08-27
AU2025201781A1 (en) 2025-04-10
JP7759067B2 (ja) 2025-10-23
US11325966B2 (en) 2022-05-10
CN110621338A (zh) 2019-12-27
WO2018125813A1 (en) 2018-07-05
US20200199203A1 (en) 2020-06-25
BR112019013468A2 (pt) 2020-05-19
CN116948018A (zh) 2023-10-27
AU2017387041A1 (en) 2019-07-25
EP3562505A1 (en) 2019-11-06
JP7041898B2 (ja) 2022-03-25
CN110621338B (zh) 2023-06-27
US12534515B2 (en) 2026-01-27
US20240262895A1 (en) 2024-08-08
IL267673B1 (en) 2023-03-01
IL267673B2 (en) 2023-07-01
JP2024079708A (ja) 2024-06-11
JP2020513773A (ja) 2020-05-21
IL267673A (en) 2019-08-29
BR112019013468A8 (pt) 2022-11-22

Similar Documents

Publication Publication Date Title
MX2019007738A (es) Anticuerpos contra el vih ampliamente neutralizantes y métodos de uso de ellos.
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CL2019002824A1 (es) Anticuerpos anti-lag3.
MX2023014569A (es) Anticuerpos anti-sirpa.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2019011764A (es) Composiciones limpiadoras y usos de las mismas.
WO2016149710A8 (en) Hiv-1 neutralizing antibodies and uses thereof
MX385915B (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
CL2016002455A1 (es) Anticuerpos multiespecíficos.
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
MX2018001398A (es) Anticuerpos monoclonales contra bcma.
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
CU20160187A7 (es) (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13, 13a-octahidro-2,5-metanopirido[1',2':4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
BR112021011124A2 (pt) Anelossomos e métodos de uso
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
MX2018010491A (es) Proceso para la preparacion de un conjugado anticuerpo-rifamicina.